05/26/2026  |   Lee Han-soo  |  Korea Biomedical Review

https://www.koreabiomed.com/news/articleViewAmp.html?idxno=31788 

Korea has long sold itself as one of Asia’s most reliable clinical trial destinations. The pitch has been clear -- fast recruitment, experienced investigators, high-quality data, and strong hospital infrastructure.

The U.S. FDA’s recent move to test real-time clinical trials shows where global drug development is heading. On April 28, the FDA announced two proof-of-concept real-time clinical trials and a planned pilot program designed to test how clinical trial endpoints and data signals can be reported to the agency in real time.

The agency said early-phase clinical trials remain one of the major bottlenecks in drug development, often slowed by uncertainty, limited patient populations and inefficient decision-making. By using AI-enabled tools and cloud-based data systems, the FDA aims to explore whether regulators can receive validated trial signals while a study is still underway, rather than waiting for conventional post-trial submissions.

For Korea, the message is clear. Clinical trial competitiveness can no longer be measured only by how quickly hospitals enroll patients.

The next contest will be about how quickly reliable, structured and regulator-ready data can move from trial sites to sponsors and authorities.

Korea has strong foundations. The country has built a reputation as a leading clinical trial hub in Asia, supported by major academic hospitals, concentrated patient pools, skilled investigators and relatively efficient regulatory procedures. Korea’s position is not just a policy slogan. An analysis of ClinicalTrials.gov data found that Korea ranked sixth globally and second in Asia for industry-sponsored clinical trials in 2024, while Seoul ranked second among cities worldwide, behind Beijing. The figures show that Korea remains one of the world’s most active clinical trial hubs, even as competition from China is intensifying.

These strengths have helped Korea attract global pharmaceutical companies, especially in oncology, rare diseases and early-phase development. In many cases, Korean hospitals can recruit patients quickly and generate data that global sponsors trust.

But the FDA’s real-time trial initiative points to a different kind of competition. The issue is no longer only whether Korea can enroll patients faster than other countries. It is whether Korea can generate, connect, verify and transmit clinical data in ways that fit the next generation of global development.

That distinction matters.

Traditional clinical trials have generally followed a sequential model. Trial sites collect data, sponsors clean and analyze it, and regulators review it after formal submission. Real-time clinical trial models seek to shorten that gap by allowing regulators to receive selected safety, efficacy or endpoint signals while a trial is ongoing.

If this model expands, countries with strong hospitals but fragmented data systems may find themselves at a disadvantage. Sponsors will increasingly look for sites and countries that can support digital source verification, remote monitoring, AI-assisted safety review, electronic patient-reported outcomes, wearable data and cloud-based regulatory communication.

Korea is not starting from scratch. Major hospitals already operate advanced electronic medical record systems, while the country has strong national health insurance data infrastructure and ongoing projects related to decentralized clinical trials, including remote monitoring, electronic consent and electronic patient-reported outcomes.

Korean policy circles are also paying attention. A recent KHISS Global Bio-Health Industry Trend report highlighted the FDA’s real-time clinical trial initiative and broader use of AI and cloud-based systems in drug development.

But recognition alone is not enough. Korea’s challenge is to turn separate digital trial efforts into a connected national capability.

The country’s clinical trial ecosystem remains heavily centered on large hospitals. That model has been highly effective for site-based recruitment and investigator-led execution. However, it is less naturally suited to a future in which patients may participate remotely, data may be captured continuously and regulators may expect faster access to structured trial signals.

This is where Korea’s next task lies. Hospitals, regulators, sponsors, CROs and technology companies need to work from a shared framework for data interoperability, privacy protection, cybersecurity, AI validation and cloud use in clinical trials. Without that, Korea may remain fast at recruiting patients but slow at producing real-time, regulator-ready data.

The risk is not that Korea will lose its clinical trial competitiveness overnight. The risk is that Korea continues to define competitiveness by yesterday’s metrics while global sponsors and regulators move toward tomorrow’s standards.

Fast recruitment helped Korea become a preferred clinical trial destination. High-quality investigators and hospital infrastructure remain powerful advantages. But the next phase of competition will be decided by data connectivity, regulatory agility and the ability to support more adaptive, digital and real-time development models.

For Korea, the FDA’s initiative should be seen less as a U.S. regulatory experiment and more as an early signal of where global clinical trials are heading.

The country’s clinical trial edge is still strong. But to remain competitive, Korea must move beyond the idea that speed means only faster enrollment.

In the next era, speed will mean something broader -- faster data flow, faster regulatory learning and faster evidence generation.

Korea’s future as a clinical trial hub will not be decided only by how quickly patients enter studies. It will be decided by how well the country connects the data behind them.

05/26/2026  |  Allan Polendey Dumlao  |  Synapse

https://synapse.ucsf.edu/articles/2026/05/26/missing-patients-clinical-trials

Health equity has become a key focus in healthcare and biomedical research. However, in clinical trials, equity is often only addressed during the recruitment phase, when clinicians discuss with patients whether to participate in studies that might provide a potential treatment or cure. These conversations are important but occur too late. 

By the time a patient is approached, many of the most critical decisions about who can realistically participate have already been made. The eligibility criteria, visit schedules, data requirements, and operational assumptions have quietly influenced the design of trials. At that point, health equity is no longer a matter of design; it becomes a negotiation.

Although most clinical trials succeed operationally, they may still fail to represent the populations most affected by disease. This results not only in health inequity but also potential missed scientific opportunities, leading to evidence that does not fully translate into real-world practice.

As a nurse working in clinical oncology and in biotechnology, the gap between trial design and real-world patients is hard to ignore. In clinical settings, clinical outcomes are rarely explained solely by patient behavior. When a discharge plan fails, clinicians don't assume patients lack motivation. Instead, we ask whether transportation was available, medications were affordable, health insurance exists, caregiving support was present, and whether instructions were realistic given the patient’s circumstances. Healthcare trains us to think this way - systems shape outcomes. The same reasoning applies when adherence issues occur. Clinicians are taught to look beyond intent. We consider the complexity, burden, access, and feasibility. When adherence fails, it often indicates a system that is misaligned with patients’ realities.

Clinical trials face the same reality. Clinical trial designs incorporate assumptions about time, flexibility, transportation, digital access, language, and social support. When these assumptions go unexamined, participation is feasible only for a limited group of patients, often those already overrepresented in research.

Designing trials around an idealized participant rather than real patient populations can produce evidence that is technically sound but clinically incomplete. These limitations become apparent later through uneven treatment responses, unexpected safety signals, and gaps between trial results and real-world outcomes. This represents a missed scientific opportunity. Patient representation is not just an equity issue; it is essential for reliable science.

Biotech and pharmaceutical companies influence participation conditions long before recruitment begins. Decisions on eligibility criteria, visit burden, operational complexity, and data collection requirements determine who can realistically enroll.

However, education about health equity often focuses on clinicians and study sites. They are asked to solve recruitment challenges after structural decisions are already made. This is not a matter of intent but of connecting trial design choices to their real-world impacts.

Evidence from insufficiently diverse patient populations weakens the generalizability of findings. Trials designed to promote broader participation generate data that more accurately reflect disease burden, treatment response, and safety across diverse populations. Therefore, health equity and data quality are not competing priorities. They are inseparable in rigorous scientific research.

Advocacy has long been a core value in healthcare communities. Clinicians are trained to anticipate harm, identify exclusion, and intervene when systems fail patients. These same principles should extend to the biotech and pharmaceutical industries, especially for those involved in designing, building, and conducting clinical trials, as a core competency or part of responsible research.

Clinical research aims to guide care for real people. Therefore, health equity cannot remain a downstream aspiration. It must be integrated into the design process: taught, expected, and measured among the teams that shape the eligibility criteria, operational burdens, and participation pathways. The biotech and pharmaceutical industries, whose trials generate evidence guiding treatment, must actively partner in advancing health equity.

The patients missing from clinical trials are rarely absent by chance. They are the product of decisions made long before recruitment begins.

05/26/2026  |  Ella Hohmann  |  AJMC

https://www.ajmc.com/view/car-t-cell-therapy-biomarkers-clinical-trials-and-bladder-cancer-advances 

Discussions highlighted implementing innovative treatments and ensuring patients treated in the community setting have equitable access to advanced therapeutics.

The pace of innovation in oncology has created both extraordinary opportunity and significant complexity for clinicians practicing across the full spectrum of care settings. From novel immunotherapy combinations in myeloma and bladder cancer to the challenge of ensuring that patients in community settings can access biomarker testing and clinical trials, the gap between what is possible and what is routinely delivered remains a defining issue.

The American Journal of Managed Care® brought together academic and community oncologists, pharmacists, and urologists in Cincinnati, Ohio, on April 14, 2026, for the Institute for Value-Based Medicine® event “Pioneering the Next Era of Oncology Care,” to examine how evidence, innovation, and collaboration can be translated into better patient outcomes.

Scaling Innovation: Delivering Targeted Therapies in Multiple Myeloma
In the opening panel, experts weighed chimeric antigen receptor (CAR) T-cell therapy vs bispecifics in myeloma, debating therapy sequencing, minimal residual disease (MRD)–guided decisions, infection management, and the emerging concept of functional cure. Edward A. Faber Jr, DO, MS, director of the adult bone marrow transplant and cellular therapy program and associate clinical professor of hematology/oncology at the University of Cincinnati (UC), served as the panel moderator and asked the panelists how they approach treatment decisions in an era of over 20 drug options, multiple combination treatments, and transplants as options.

Mark A. Marinella, MD, FACP, assistant clinical professor of medicine and oncologist/hematologist at Wright State University School of Medicine and Dayton Physicians Network, described his community-based approach by explaining that he initiates standard quadruplet induction in transplant-eligible patients and refers to academic partners for transplant evaluation. However, he acknowledged that the practice landscape is shifting. “It’s the most complicated cancer to treat,” he said, “because the data just change every week.”

Pierluigi Porcu, MD, professor of medicine and division chief of hematology and cellular therapy at the University of Kentucky College of Medicine, framed the central tension as a question of MRD. With modern frontline quadruplet regimens producing deeper responses than 3-drug regimens, MRD-guided decision-making is increasingly informing whether and when transplant is warranted. Nonetheless, he stated that autotransplants remain the standard of care, but acknowledged that this is changing. “I like to be cautious about completely changing certain patterns of care,” Porcu noted. In the community setting, MRD testing remains a source of uncertainty, with Marinella noting that outside of clinical trials, routine MRD testing in the community has lagged.

Jason Ernstberger, PharmD, BCOP, clinical hematology, oncology, cellular therapy pharmacist and director of the PGY-2 oncology residency program at University of California Medical Center, states that patient preference plays a meaningful role in deciding long-term treatment and said that “asking the patient is really important, because some patients might just have a lot of anxiety going off therapy—it’s like their crutch.”

The panel then turned to the operational realities of administering bispecific antibodies. Ernstberger outlined step-up dosing protocols for teclistamab, noting that an accelerated 48-hour interval between step-up doses was being used to shorten hospitalizations. He also described a strategy of liberal dexamethasone use in place of prophylactic tocilizumab to reduce the incidence and severity of cytokine release syndrome. Porcu reported that his institution was beginning to roll out outpatient step-up dosing for lymphoma bispecifics as a first step before extending the approach to myeloma bispecifics.

Beyond clinical protocols, structural barriers to bispecific access remain prevalent. Porcu noted that approximately one-third of patients in the University of Kentucky’s catchment area in Eastern Kentucky face inadequate caregiver support, which is important for safe outpatient bispecific administration. “Caregiver support adequate to deliver some of these complex therapies is a big problem,” he said. Marinella echoed this from the community perspective, noting that transportation and lack of family caregivers present greater practical barriers than insurance coverage in many cases.

The panel concluded by touching on the concept of “functional cure” in myeloma. Porcu defined it not as a biological elimination of tumor cells but rather as a state in which durable MRD-negative remission allows for therapy discontinuation and disease equilibrium. “The functional part probably means that ‘I’m not 100% sure I’m cured,’ so it still requires surveillance,” he said, “but the cure part, in my judgment, really has to have a discontinuation of therapy.”

Precision in Practice: From Biomarkers to Bispecifics in Lung Cancer
James F. Maher, MD, a medical oncologist at TriHealth and the panel moderator, opened by noting that his program’s biomarker testing rate, which had been only 65%, had climbed to 97% following electronic health record (EHR) integration. This change, he explained, allowed the team to track turnaround time, treatment initiation delays, and testing gaps directly from within the clinical workflow.

Zhonglin Hao, MD, PhD, coleader of the thoracic oncology program at the University of Kentucky Markey Cancer Center (Markey), and Rajeev Kulkarni, MD, hematologist/medical oncologist at Dayton Physicians Network, agreed on the imperative of reflex, upfront testing at the time of diagnosis. “As soon as we have cancer, we need to know the biology,” Hao said. “In the clinic, I routinely tell my patients, ‘That’s our goal, to get tested, because we need to know the biology to dispense the best treatment for you.’” Kulkarni, representing the community perspective, emphasized precision and actionability over breadth.

The panelists also discussed Medicare’s 14-day rule, which bundles lab tests into hospital payments when ordered within 14 days of discharge, creating financial disincentives and ultimately leading hospitals to delay testing. The panelists note that this can generate significant financial liability when next-generation sequencing testing is ordered during a hospital admission. Hao described a “financial toll” of more than $80,000 incurred. His institution has developed workarounds, including coordinating test orders through outpatient procedures performed between hospitalizations and timing orders to occur after hospital discharge.

 The session also addressed the rapid integration of tarlatamab, a bispecific T-cell engager, into outpatient treatment programs. Kulkarni reported that his group was among the first in Dayton to offer outpatient tarlatamab, and Hao described a similarly smooth outpatient experience, with plans to further reduce hospitalization requirements. Both panelists emphasized the value of established institutional protocols in Epic, trained nursing staff, and close collaboration with their colleagues in the intensive care and pulmonology departments in enabling safe outpatient administration.

Looking ahead, the panelists anticipated continued acceleration in the approval of targetable biomarkers across earlier lines of therapy and the neoadjuvant setting. “Speedy, prompt testing before we are able to initiate treatment is key,” Hao observed, noting that delays attributable to biomarker testing, although frustrating for patients, are ultimately less costly than the downstream consequences of empiric, unguided treatment.

Collaborations in Today’s Environment for Successful Clinical Trials
The third panel, moderated by Jennifer Vaughn, MD, associate professor and hematology specialist at The Ohio State University Wexner Medical Center, tackled what may be one of the most systemically challenging issues in oncology: how to make clinical trials accessible to the patients who need them most.

Brian Mulherin, MD, of Hematology Oncology of Indiana and medical director of the American Oncology Network, shared that adult patients with cancer enroll in clinical trials at rates below 10% nationally, a rate that is especially low compared with that of pediatric oncology, where trial participation is often the default. Trial eligibility criteria are often built around idealized patients and may exclude the people most likely to be seen in community practices. Liberalizing those criteria, he said, is an important step the oncology community needs to ensure “you can actually recruit the patients that you are likely to see in a real-world setting.”

Rachael Morgan, PharmD, BCOP, clinical pharmacist and hematology/oncology pharmacy research and formulary manager at Markey, emphasized structural solutions such as decentralized trial designs that incorporate telehealth visits, remote monitoring devices, home phlebotomy, and mail-order drug delivery. These options, she said, can substantially reduce the burden of trial participation for patients who face transportation, childcare, or employment barriers. “By sequestering clinical trials in academic medical centers,” she noted, “we definitely limit not only our ability to enroll patients into those trials, but also [to] offer those treatments for those patients. Ultimately, I think the adjustment of trial designs and the development of decentralized clinical trials is a good strategy for this.”

The panelists also touched on the erosion of public trust in clinical research following the COVID-19 pandemic, which has since been amplified through social media and artificial intelligence–generated health content. Mulherin stated that physicians can no longer rely solely on the clinical encounter to counteract that distrust and need to be out in the community and online doing advocacy work. “There needs to be somebody on TikTok saying, ‘What is a clinical trial?’ and ‘What is a placebo arm?’ That’s what we need,” he said.

Vaughn also asked the panelists about the persistent tension between academic and community oncology practices in patient referral and trial access. Mulherin believes this is changing as physicians are starting to communicate better and more consistently with one another to give updates on patients. Morgan suggested making tumor boards accessible to community oncologists for real-time consultation, sharing trial-related order sets and educational materials across affiliate networks, and ensuring robust communication when patients are referred to an academic center for trial enrollment and then return home. She also proposed a compelling model that has been used outside of oncology but that she thinks could be applicable here as well, whereby the academic medical oncologist and the community oncologist have a paired telehealth appointment with the patient, combining the community physician’s longitudinal knowledge of the patient with the academic center’s trial expertise.

Advancing Customized Care in the Treatment of Bladder Cancer
“The initial transurethral resection,” Alberto Martini, MD, assistant clinical professor and director of research in the Department of Urology at the University of Cincinnati (UC) College of Medicine, says, “is generally the first procedure that we perform to diagnose and also to treat bladder cancer. It’s very important to do it thoroughly.” He reviewed some components of a high-quality transurethral resection of bladder tumor, including blue light cystoscopy to detect carcinoma in situ and occult flat lesions, procedural checklists, and early postoperative intravesical chemotherapy. He notes that these steps are evidence-based and cost-effective but inconsistently implemented.

The discussion then moved to risk stratification and the increasingly crowded landscape of agents for BCG-unresponsive non–muscle invasive bladder cancer. BCG has been the standard-of-care drug that has been around for over 4 decades; however, it does fail patients sometimes. Kamal Pohar, MD, chair of the Department of Urology at UC, who moderated the panel, shifted the conversation to discuss some of the current FDA-approved options in this space, including pembrolizumab and the combination of intravesical gemcitabine and docetaxel, which has generated compelling real-world evidence, although it is not yet the subject of a randomized trial.

Zin Myint, MD, medical oncologist at Markey, noted that although pembrolizumab produces a complete response in approximately 41% of patients, the systemic toxicity profile—with grade 3 or higher adverse events in approximately 20% of patients—must be weighed carefully in a population for whom radical cystectomy remains a potentially curative option. “Quality of life and what options are left, and whether patients want to preserve bladder [function]—these are the most important things,” Myint said.

Pohar introduced recently published data from a Patient-Centered Outcomes Research Institute–supported randomized trial comparing radical cystectomy with continued intravesical therapy in patients who preferred bladder preservation. Patients who underwent cystectomy reported superior outcomes across multiple quality-of-life domains. Martini explained that he “integrated this by not offering too many lines of therapy before pushing for a cystectomy.” He noted that repeated cystoscopies, procedures, and the psychological burden of recurrent cancer carry their own significant quality-of-life costs.

Myint reviewed the transformative impact of the EV-303 trial (NCT03924895) of neoadjuvant enfortumab vedotin plus pembrolizumab (EV-pembro) in the cisplatin-eligible population. Subsequent data from EV-304 (NCT04700124) have extended this finding to cisplatin-ineligible patients with similar efficacy. She noted that she had already begun using EV-pembro as neoadjuvant therapy in cisplatin-eligible patients, often securing insurance authorization despite the regimen’s pending formal approval status for that indication.

The session concluded with a discussion of circulating tumor DNA’s (ctDNA) growing role in bladder cancer. Myint described the prognostic signal from the NIAGARA study (NCT03732677), in which baseline ctDNA positivity correlated with poorer outcomes, while conversion to ctDNA negativity was associated with improved prognosis. Pohar noted, “There is a lot of enthusiasm in the field about the benefit of ctDNA. It’s under in-depth study in various areas, but is starting to be utilized quite a bit in clinical practice as a tool to make treatment decisions.” 

05/26/2026 | Novo Jornal

https://www.novojornal.com.br/pesquisa-brasileira-desenvolve-terapia-celular-contra-complicacoes-apos-transplantes/ 

Researchers at the Pontifical Catholic University of Paraná are developing a groundbreaking cell therapy in Brazil to combat serious complications associated with bone marrow transplantation. The experimental treatment uses mesenchymal stem cells and has already shown promising results in controlling graft-versus-host disease, known by the acronym GVHD.

The complication occurs when immune cells present in the donated bone marrow begin to attack the recipient's body after the transplant. The disease can appear within the first hundred days after the procedure, characterizing the acute form, or manifest years later, in the chronic version.

In acute cases, the most affected areas are usually the skin and the gastrointestinal system, causing symptoms such as redness, burning, cramps, nausea, and changes in liver function. The chronic form can affect different organs and cause stiffness, respiratory difficulties, and lesions on the skin and mucous membranes.

Currently, the traditional treatment for GVHD is done with corticosteroids and immunosuppressant drugs, used to reduce the inflammation caused by the reaction of the immune cells. However, some patients do not respond adequately to conventional therapies or experience severe side effects due to the toxicity of the medications.

The new alternative developed by PUCPR is called MesenCell. The treatment uses mesenchymal stem cells taken from the bone marrow of healthy donors. These cells undergo specialized laboratory processing and remain frozen until application in patients.

Carmen Kuniyoshi Rebelatto, technical director of the Cellular Technology Center at PUCPR and coordinator of the project, explained that the therapy aims to act directly on the origin of the disease, reducing the activity of immune cells responsible for inflammation.

According to the researcher, T and B cells are the main culprits in attacking the organism of transplanted patients. The cell therapy developed by the university manages to decrease the proliferation of these cells and modulate the immune system, reducing the inflammatory process.

Initially, the treatment should be indicated mainly for patients who do not improve with traditional medications or who cannot use them due to toxic effects. Another problem pointed out by the researchers is that some of the currently recommended treatments are not available in the Brazilian Unified Health System (SUS).

The research group has already completed a pilot study involving eleven patients diagnosed with chronic GVHD. In this initial stage, the same stem cells were used, but combined with another substance used in therapeutic preparation.

The results observed were considered encouraging by the researchers. Half of the participants showed complete remission of the disease. Furthermore, the treatment resulted in a seventy-five percent improvement in gastrointestinal impairments and complete recovery from skin symptoms observed among the patients monitored.

According to Carmen Rebelatto, some participants presented with scleroderma, a condition that causes progressive hardening of the skin and loss of body mobility. According to the researcher, the therapy managed to reverse this condition in some of the cases evaluated.

The new phase of clinical studies will begin in September and should involve twenty patients. The tests will be conducted at three reference centers in Paraná: the Hospital de Clínicas Complex of the Federal University of Paraná, the Erasto Gaertner Hospital, and the Nossa Senhora das Graças Hospital.

The project receives funding from the Financing Agency for Studies and Projects (FINEP) and the National Council for Scientific and Technological Development (CNPq). After the completion of the next clinical stages, the researchers intend to seek partnerships with the pharmaceutical industry to expand the production of the drug and enable future large-scale applications in the country.

05/26/2026 | Gustavo Bottós de Paula | Migalhas.com

https://www.migalhas.com.br/depeso/456531/lgpd-na-saude-prontuario-sigilo-e-direitos-do-paciente 

The new Patient Statute reinforces that hospitals, clinics and doctors must treat health data with safety, transparency and respect for patient autonomy.

Data protection as part of health care

With the entry into force of Law 15.378/26, which instituted the Statute of Patient Rights, it reinforces a reality that has come into being by the LGPD: health information cannot be treated as a mere administrative record.

The medical record, the exams, the reports, the prescriptions, the cadastral data, the clinical histories and the information about companions, family members and responsáveis ​​integrate a sensitive ecosystem, legally protected and directly linked to human dignity.

The LGPD, law 13.709/18, classifies as sensitive personal data or data on racial or ethnic origin, religious conviction, political opinion, affiliation to a union or an organization of a religious, philosophical or political nature, data referring to health or sexual life, genetic or biometric data, when linked to a natural person. This means that public and private hospitals, clinics, laboratories, clinics, operators, doctors and other health professionals must adopt a reinforced level of care and treatment of information.

It's not just about avoiding leaks. The aim is to ensure that the collection, use, storage, sharing and discarding of data are linked to legitimate, specific, necessary and transparent purposes.

The record as a technical, legal and sensitive document

The patient's record is more sensitive to the discussion. It does not belong freely to the hospital, clinic or doctor as it contains an internal file without limits. It also cannot be understood in a simplistic way as a document available without criteria to anyone interested.

The record is, at the same time, a technical instrument of assistance, a documentary evidence of professional work and a repository of sensitive patient data. Therefore, your access must comply with health legislation, ethical-professional standards, secrecy and LGPD principles.

The Patient Statute reinforces this reading to reconstitute the centrality of clear information, the autonomy and participation of the patient in the decisions relative to their care.

A practical consequence is evident: the more the legal order strengthens the patient's right to information and self-determination, the more it becomes necessary for health institutions to organize their internal flows of access to records, delivery of copies, document storage, registration of consents, sharing with third parties and protection against undue access.

Nem everything depends on consent

In the health field, it is common that the treatment of sensitive people does not depend exclusively on the patient's consent. The LGPD admits other legal bases, especially when the treatment is indispensable for the protection of health, for the execution of public policies, for the fulfillment of legal or regulatory obligations, for the protection of life or for physical safety, for the conduct of studies by research organizations, or for regular exercise of rights in judicial, administrative or arbitral proceedings.

Ainda assim, this does not authorize indiscriminate treatment. The existence of a legal basis does not eliminate the obligation to observe purpose, adequacy, necessity, security, prevention and responsibility.

This point is decisive. Many establishments still treat LGPD as a law of consent, imagining that it would be enough to insert a generic clause in service forms. In the health area, this understanding is insufficient.

Consent, when used, must be free, informed, unequivocal and specific. Therefore, in various situations, assistance may be different on an adequate legal basis. The error is both in requiring consent for everything, and in dispensing with any legal basis analysis. The correct thing is to map each data processing operation and identify its purpose, its legal basis and its risk level.

Compartment of dice and everyday risks

Hospitals and clinics must pay special attention to the sharing of information. The sending of records through messaging applications, the use of systems without access control, the circulation of exams in internal groups, the unnecessary printing of documents, the transfer of data to outsourced companies, the communication with family members without adequate authorization and the provision of information by telephone. Correct situations that could lead to serious legal exposure.

The LGPD requires technical and administrative measures capable of protecting personal data against unauthorized access and accidental or illicit situations of destruction, loss, alteration, communication or diffusion.

In practice, this requires clear rules on what the record can be accessed, in what circumstances, for what purpose and through what form of registration. It also requires that electronic systems have differentiated levels of permission, access logs, individual data, secure authentication and traceability mechanisms.

The problem is not just a large number of dice. Many times, infração arises from seemingly small behaviors, such as photographing a computer screen, leaving a care record on display on the balcony, sending a test for the wrong contact or commenting on a clinical case in an inappropriate environment.

Public hospitals and public treatment purposes

Not the public sector, the challenge is even broader. Public hospitals, basic health units, municipal and state secretariats, regulatory centers and computerized systems of their treatment are given on a large scale, many times in contexts of social vulnerability.

The LGPD admits the processing of data by public power for the execution of public policies, but requires public purpose, transparency, security and respect for the rights of two holders. Due to the need for administrative efficiency, it cannot serve as a generic authorization for undue exposure of patient data.

It is essential that public health organizations organize access flows, define responsibilities, train servers, provide outsourced guidance and adopt security policies that are compatible with the sensitivity of the information being processed.

The digitalization of public health services is necessary and positive, but it is necessary to walk together with governance, control and prevention of risks. The greater the data, the greater the institutional care must be.

Clinics, clinics and free professionals are also subject to LGPD

The LGPD does not only apply to large hospitals or healthcare operators. Small clinics, medical offices, laboratories, self-employed professionals, physiotherapists, psychologists, dentists, nutritionists and other agents who treat health conditions must also observe their rules.

The scale may vary, but the sensitivity of the given remains the same. A small office that prepares records, receives exams by applications, schedules consultations through digital systems or shares information with agreements and also processes sensitive data.

For doctors and other health professionals, LGPD must be understood together as professional secrecy. Owing to confidentiality, it did not exist before the LGPD, but has expanded the accountability mechanisms and introduced a language of data protection.

Assim, it is not enough that the professional has good faith or intention to assist. It is necessary to adopt specific protective measures: do not leave exposed records, do not share images of patients on an adequate legal basis, do not disclose identified clinical cases on social networks, do not allow the use of logins by third parties and do not store sensitive documents on unsecured devices. minimum security.

Governance, training and institutional responsibility

Another essential aspect is governance. Compliance with the LGPD does not mean the existence of a privacy policy on the site or the availability of a generic thermos for patients.

Health institutions must maintain data inventory, access control, confidentiality rules, equipment training, appropriate contracts with suppliers, incident response plan, document retention and disposal criteria, service channel for holders and indication of responsibility for the processing of personal data, when apply it.

The government must also reach receptionists, administrative teams, staff, information technology, nursing, clinical staff, outsourced providers and contracted companies. In health, or given sensitivity circulates through many sectors. Therefore, protection cannot depend solely on the legal sector or the technology area.

An institution that does not train its team, does not document its decisions and does not control its access assumes high risk. In any event, it will not be enough to affirm that there was a formal policy. It will be necessary to demonstrate effective prevention, control and response measures.

Privacy by design and privacy by default in health systems

Another essential point for hospitals, clinics, laboratories, operators, clinics and public health organizations is the incorporation of privacy by design and privacy by default in data management systems.

Privacy by design means that data protection must be thought through from the conception of the system, the flow of care, the electronic record, the scheduling platform, the telemedicine tools or any technological solution used in health care. Privacy cannot be treated as a post-adjustment, applied only after the system is already in operation. It must be integrated into the architecture of the solution from the beginning.

Privacy by default does not require that, by default, the systems operate with the highest reasonable level of protection for these people. Isso means limiting access, reducing the queue to the minimum necessary, preventing unnecessary viewing, restricting permissions by professional profile, recording access logs, controlling exports, blocking unnecessary compartments and preventing sensitive information that is available to people who do not directly participate in it. assistance, management or legally authorized purposes.

In the health area, these concepts are especially relevant because the given treaty is, in a real, sensitive way. A poorly configured electronic medical record system can allow professionals without a link to the care to access clinical records, exams, diagnoses, prescriptions and intimate patient information. Likewise, platforms without traceability make it difficult to identify unintended access and commit to responsibility in the event of an incident.

The adoption of privacy by design and privacy by default requires that health systems be structured with secure authentication, access profiles compatible with enforced functionality, information segregation, cryptography when adequate, audit trails, abnormal use alerts, blocking mechanisms, backup routines, security policy. retention and discarding of data and periodic review of granted permits.

This care must be taken to achieve both own systems and solutions contracted from third parties. Before contracting software for electronic medical records, telemedicine, hospital management, cloud storage, scheduling, query marking or patient relations, the institution must ensure that the provider observes adequate security, confidentiality, traceability and compliance standards with the LGPD.

In practice, it is not enough that a hospital or clinic has good internal rules if the system used allows broad access, automatic compartments, generic information or the absence of control over the display of certain information. Technology must be allied with data protection, and not a silent gateway for privacy violations.

Therefore, the implementation of these principles represents a change in mentality. Instead of asking just how to correct a leak after it happens, health institutions must ask how to devise their processes and systems to reduce, from the beginning, the chance of untimely exposure. In order to protect health, prevent undue access to data and also preserve patient confidence and the integrity of the healthcare relationship.

Research, teaching and secondary use of health data

Scientific and academic research in the health area also demands caution. Patient data may be relevant for epidemiological studies, clinical research, technological innovation and public policy endorsement.

Therefore, whenever possible, anonymization or pseudonymization techniques, access limitation, data minimization and ethical approval must be adopted when required. The health data does not lose its sensitivity just because it was relocated from the healthcare environment to the scientific environment.

It also deserves attention or use of data for systems training, artificial intelligence, internal audits, academic publications, classrooms, conferences and dissemination of clinical cases. The secondary use of patient information requires an adequate legal basis, compatible purposes and reinforced protective measures.

The exhibition of images, exams or clinical narratives on social networks, even though with educational intent, may represent ethical and legal violations, direct or indirect identification of the patient is permitted.

Patient Statute and a new information culture

The Patient Statute tends to deepen this cultural change. To reconfirm issues related to information, dignity, autonomy, safety and patient participation, it is now important that data protection be seen as part of healthcare quality.

Privacy is not an obstacle to care. On the contrary, it is an element of trust that sustains the relationship between patient, professional and institution.

Health information needs to be accessible to the patient, but protected against unauthorized third parties. This balance will be one of the central issues in contemporary medical practice: guaranteeing the patient's right to know, access, and understand their data, without transforming sensitive information into content vulnerable to undue exposure.

Legal Consequences of Undue Exposure

A breach of health data can generate multiple consequences. There is a risk of administrative sanctions by the ANPD - National Data Protection Authority, civil liability, professional ethical repercussions, reputational damage, and, in some cases, individual or collective litigation.

In a sector marked by intimate information, sensitive diagnoses, stigmatizing diseases, family history, genetic conditions, and situations of fragility, a leak can cause damage that goes far beyond embarrassment.

Liability can extend to institutions, managers, professionals, and contracted operators, depending on their conduct, the degree of control over data processing, and the measures adopted before, during, and after the incident.

Therefore, the issue should be treated as a strategic priority, not merely as a documentary requirement.

Conclusion: Protecting data is protecting people

Compliance with the LGPD (Brazilian General Data Protection Law) should not be treated as imported bureaucracy into medical routines. It is now part of the legal duty of care.

Hospitals, clinics, and professionals who handle medical records and sensitive data need to understand that protecting patient information is an extension of protecting the person themselves.

The new patient rights legislation only makes more evident what the LGPD already announced: contemporary healthcare demands technology, efficiency, and data integration, but also responsibility, transparency, and respect for privacy.

In times of electronic medical records, telemedicine, artificial intelligence, system interoperability, and instant communication, protecting health data has ceased to be an accessory precaution. It has become a requirement of legality, professional ethics, and institutional trust.